CABA Stock: Insider Activity, Filings & Research
Cabaletta Bio, Inc. (CABA) — Drillr’s hub for CABA insider activity, SEC filings, earnings signals and AI research.
CABA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 2, 2026 | Gerard Michaelofficer: General Counsel | Grant | 175,000 | $3.30 |
| Mar 2, 2026 | Das Arunofficer: Chief Business Officer | Grant | 175,000 | $3.30 |
| Mar 2, 2026 | Binder Gwendolynofficer: President, Science & Tech. | Grant | 225,000 | $3.30 |
| Mar 2, 2026 | Chang David J.officer: Chief Medical Officer | Grant | 225,000 | $3.30 |
| Mar 2, 2026 | Nichtberger Stevendirector, officer: President & CEO | Grant | 674,000 | $3.30 |
| Mar 2, 2026 | Marda Anupofficer: Chief Financial Officer | Grant | 225,000 | $3.30 |
| Jan 21, 2026 | Simon Markdirector | Buy | 11,061 | $2.28 |
| Jan 21, 2026 | Gerard Michaelofficer: General Counsel | Buy | 6,600 | $2.27 |
| Jan 21, 2026 | Chang David J.officer: Chief Medical Officer | Buy | 8,800 | $2.26 |
| Jan 21, 2026 | Binder Gwendolynofficer: President, Science & Tech. | Buy | 11,312 | $2.19 |
| Jan 21, 2026 | Tomasello Shawndirector | Buy | 22,725 | $2.21 |
| Jan 21, 2026 | Gavel Steveofficer: Chief Commercial Officer | Buy | 22,170 | $2.27 |
| Jan 21, 2026 | Bollard Catherinedirector | Buy | 4,405 | $2.27 |
| Jan 21, 2026 | Nichtberger Stevendirector, officer: President & CEO | Buy | 45,000 | $2.24 |
| Oct 15, 2025 | Gavel Steveofficer: CHIEF COMMERCIAL OFFICER | Grant | 275,000 | $2.49 |
Source: CABA SEC Form 4 filings, latest Mar 2, 2026. For informational purposes only — not investment advice.
Cabaletta Bio, Inc. company profile
Overview
Cabaletta Bio, Inc. (NASDAQ:CABA) is a clinical-stage biotechnology company founded in 2017 and headquartered in Philadelphia, Pennsylvania. Originally incorporated as Tycho Therapeutics, Inc., the company changed its name to Cabaletta Bio in August 2018 and went public in October 2019. Cabaletta focuses on developing engineered T cell therapies specifically designed to treat B cell-mediated autoimmune diseases, representing a novel approach in the rapidly evolving field of cellular immunotherapy.
Business
Cabaletta Bio operates in the biotechnology sector, specifically within the emerging field of engineered T cell therapy for autoimmune diseases. The company's core innovation centers around Chimeric Autoantibody Receptor (CAAR) T cell technology, a proprietary platform that represents a significant departure from traditional autoimmune disease treatments. To understand Cabaletta's approach, it's important to recognize that many autoimmune diseases are caused by B cells that produce harmful autoantibodies - proteins that mistakenly attack the body's own tissues. Traditional treatments often involve broad immunosuppression, which can leave patients vulnerable to infections and other complications. Cabaletta's CAAR T cells are engineered to act like guided missiles, selectively targeting and eliminating only the specific B cells that produce disease-causing autoantibodies, while leaving healthy immune cells intact. The company's product pipeline includes several CAAR T cell therapies at various stages of development. DSG3-CAART is the lead product candidate, currently in Phase I clinical trials for treating mucosal pemphigus vulgaris, a rare autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. The pipeline also includes MuSK-CAART for myasthenia gravis (a muscle weakness disorder), FVIII-CAART for certain Hemophilia A patients, and DSG3/1-CAART for mucocutaneous pemphigus vulgaris, all in preclinical or discovery stages. As a clinical-stage company, Cabaletta currently generates no revenue from product sales, with all financial resources dedicated to research and development activities.
Revenue model
As a pre-revenue biotechnology company, Cabaletta Bio does not currently generate income from product sales or services. The company operates on a traditional biotech business model, funding its operations through equity financings, grants, and potential future partnerships while advancing its product candidates through clinical development. The company's future revenue model will likely center on product sales of approved CAAR T cell therapies, which would be administered as one-time or infrequent treatments for patients with specific autoimmune conditions. Given the specialized nature of these therapies and the rare diseases they target, Cabaletta would likely price its treatments as premium specialty pharmaceuticals, similar to other cell and gene therapies that command prices in the hundreds of thousands of dollars per treatment. The company also maintains research collaborations with the University of Pennsylvania and The Regents of the University of California, which may provide additional funding sources and could lead to licensing opportunities or milestone payments. Several factors could significantly impact Cabaletta's future profitability. Positive clinical trial results would be the primary driver of value creation, as successful trials could lead to regulatory approval and market access. Conversely, clinical failures or safety concerns could eliminate revenue potential entirely. The competitive landscape in autoimmune therapeutics continues to evolve rapidly, with large pharmaceutical companies and other biotechs developing alternative approaches. Regulatory pathways for novel cell therapies remain complex and potentially lengthy, affecting time to market and development costs. Additionally, manufacturing scalability and costs for personalized cell therapies represent significant operational challenges that could impact margins, while reimbursement policies from healthcare payers will ultimately determine market access and pricing power.
Competitive moat
Cabaletta Bio's competitive moat is primarily built around its proprietary CAAR T cell technology platform and specialized expertise in targeting B cell-mediated autoimmune diseases. The company's approach represents a novel mechanism of action that differs from traditional immunosuppressive therapies and other emerging cell therapy approaches, potentially providing a first-mover advantage in specific autoimmune indications. The company's intellectual property portfolio and research collaborations with leading academic institutions like the University of Pennsylvania strengthen its competitive position. The technical complexity of engineering and manufacturing CAAR T cells creates barriers to entry, as does the specialized knowledge required to identify appropriate autoantibody targets and develop corresponding therapies. However, Cabaletta's moat faces several significant challenges. The biotechnology sector is highly competitive, with numerous well-funded companies and pharmaceutical giants pursuing various approaches to autoimmune disease treatment. Large pharmaceutical companies possess substantially greater resources for research, development, and commercialization, and could potentially develop competing technologies or acquire smaller competitors. The company's focus on rare autoimmune diseases, while potentially reducing direct competition, also limits the total addressable market size. Additionally, the clinical risk inherent in all biotechnology companies represents a fundamental vulnerability - failed clinical trials could eliminate the company's competitive advantages entirely. The regulatory pathway for novel cell therapies remains uncertain, and manufacturing challenges could provide opportunities for competitors with superior operational capabilities. Overall, while Cabaletta has established a differentiated technological approach, its moat remains relatively narrow and vulnerable to both clinical and competitive pressures.
Risks & safety
Cabaletta Bio presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong liquidity but inherent business model risks. • Liquidity position: Strong cash position of $131.8 million as of Q1 2025, with minimal debt and current ratio of 4.0, providing substantial runway for operations • Cash burn analysis: Quarterly operating cash flow burn of approximately $31 million in Q1 2025, suggesting roughly 4+ quarters of funding at current burn rates • Debt and solvency: Very low debt-to-equity ratio of 0.24, minimal solvency risk in near term • Valuation metrics: Trading at 0.57x book value and negative P/E ratios due to losses, suggesting potential undervaluation relative to assets • Graham Net-Net ratio: 1.78, indicating the stock trades below liquidation value of current assets minus all liabilities • Other considerations: Pre-revenue status creates binary risk profile dependent on clinical trial outcomes; strong balance sheet provides time for clinical development but no guarantee of success; rare disease focus limits market size but may reduce competition.
Recent development
Based on the available financial data, Cabaletta Bio has been primarily focused on advancing its clinical development programs while managing cash resources efficiently. The company has maintained a disciplined approach to spending, with quarterly operating cash flow burns ranging from approximately $20-31 million over the past year, demonstrating cost control as it progresses through clinical trials. The company's lead program DSG3-CAART has advanced into Phase I clinical trials for both mucosal pemphigus vulgaris and Hemophilia A with Factor VIII alloantibodies, representing significant regulatory and development milestones. This dual indication approach for the lead asset demonstrates the platform's potential versatility across different autoimmune conditions. Cabaletta has maintained its research collaborations with academic institutions, particularly the University of Pennsylvania, which continues to support the scientific foundation of its CAAR T cell platform. The company has also been expanding its pipeline with additional CAAR T cell candidates targeting different autoimmune diseases, including MuSK-CAART for myasthenia gravis and other discovery-stage programs. The company's financial management has been notable, with successful maintenance of a strong cash position through the clinical development process. The substantial decrease in stock price from over $17 in 2023 to current levels around $1.81 reflects broader biotech market conditions and the inherent risks of clinical-stage development, but also potentially creates value opportunities for the underlying technology platform.
CABA company profile · for informational purposes only — not investment advice.
Track CABA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free